Risk factor
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of CLN.WA is 25 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell